US Stock Insider Trading | AlphaTech Holdings disclosed one insider trading transaction on February 6

K-LinePoet · 2026-03-07T10:58:33+00:00

Alpha Tech Holdings (ATEC) recently disclosed that executive Sponsel David sold 60,400 shares on February 5, 2026. The company focuses on medical technology for spinal diseases, dedicated to developing and selling related surgical treatment products, with the goal of becoming a leading global spinal company.

K-LinePoet

2026-03-07 10:58:33

Abstract generation in progress

On February 6, 2026, Alphatec Holdings (ATEC) disclosed a company insider trading activity. Executive Sponsel David sold 60,400 shares on February 5, 2026.

[Recent Insider Trading]

Disclosure Date	Position	Name	Trading Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Executive	Sponsel David	February 5, 2026	Sell	60,400	13.79	833,300
February 4, 2026	Executive	Hunsaker Craig E	February 3, 2026	Sell	37,400	14.71	549,500
December 18, 2025	Director	Pelizzon David R	December 16, 2025	Sell	250,000	19.66	4,915,000
December 18, 2025	Executive	Lish Scott	December 16, 2025	Sell	19,900	19.64	390,800
December 12, 2025	Director	Demski David M	December 11, 2025	Sell	30,000	21.20	636,000
December 12, 2025	Executive	Sponsel David	December 10, 2025	Sell	21,100	20.79	438,800
December 12, 2025	Executive	Hunsaker Craig E	December 10, 2025	Sell	32,600	20.84	679,100
December 10, 2025	Shareholder with >10%	Pritzker Jennifer N., Squadron Capital Holdings LLC, Squadron Capital LLC	December 9, 2025	Sell	86,500	21.03	1,819,100
December 10, 2025	Shareholder with >10%	Pelizzon David R	December 8, 2025	Sell	221,200	21.20	4,688,700
December 10, 2025	Executive	Koning John Todd	December 8, 2025	Sell	15,300	21.45	327,500

[Company Profile]

Alphatec Holdings, Inc. was incorporated in March 2005 in Delaware. The company is a medical technology firm dedicated to designing, developing, manufacturing, and selling surgical products for spinal disease treatment, focusing on factors affecting spinal aging. The company offers a comprehensive product portfolio and pipeline addressing cervical and thoracic disc regions, covering various spinal conditions. Its main products target the global orthopedic spinal disease market. The company’s “surgical culture” emphasizes collaboration with spine surgeons to design and co-develop a range of products. Equipped with advanced manufacturing facilities, the company has a unique competitive advantage, enabling it to quickly deliver solutions to meet urgent needs of doctors and patients. Its products and systems, with enhanced functionality, attract surgeons, and a combination of products and systems provides comprehensive solutions for safe and successful spinal surgeries. All implants sold in the U.S. are approved by the Food and Drug Administration (FDA). The company’s strategic goal is to become a leading independent global spine company focused on solutions for spinal aging. Spinal aging has unique characteristics, and its solutions target patients with osteoporosis, vertebral compression fractures, scoliosis, disc degeneration, or spinal stenosis. To further differentiate its solutions, the company has integrated minimally invasive techniques and biologics into its product portfolio to improve patient outcomes.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.